Skip to content
BiologicalX

Comparison

Curcumin vs PT-141

Side-by-side of Curcumin and PT-141. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Curcumin

  • Reduces osteoarthritis knee pain comparable to ibuprofen at 1500 mg/day enhanced formulation
  • Modest antidepressant effect (SMD ~0.34) as monotherapy or SSRI adjunct in major depression
  • Standard curcumin has ~3% bioavailability; Meriva, BCM-95, Theracurmin shift absorption 5-30 fold
  • Inhibits NF-kB and COX-2; reduces hs-CRP, IL-6, TNF-alpha in chronic inflammation
  • Antiplatelet effect at higher doses; meaningful interaction with warfarin and DOACs
  • Iron chelation can contribute to deficiency in already-marginal patients

PT-141

  • Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
  • FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
  • Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
  • On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
  • Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
  • Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors

Side-by-side

Attribute Curcumin PT-141
Category natural peptide
Also known as turmeric extract, diferuloylmethane Bremelanotide, Vyleesi
Half-life (hr) 7 2.7
Typical dose (mg) 500 1.75
Dosing frequency 1 to 2 times daily with meals as needed (max once per 24 hours, max 8 per month)
Routes oral subcutaneous
Onset (hr) 2 0.75
Peak (hr) 4 1.5
Molecular weight 368.38 1025.18
Molecular formula C21H20O6 C50H68N14O10
Mechanism Inhibits NF-kB transcription factor, COX-2, and lipoxygenase; activates AMPK and Nrf2; modulates JAK-STAT and PI3K-Akt kinase signaling. Pleiotropic anti-inflammatory and antioxidant effects. Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation.
Legal status Dietary supplement (global) Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market.
WADA status allowed allowed
DEA / Rx Not scheduled Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation
Pregnancy Culinary turmeric is safe; supplemental curcumin best avoided in pregnancy Not recommended; contraindicated during pregnancy per Vyleesi label
CAS 458-37-7 189691-06-3
PubChem CID 969516 9941379
Wikidata Q312266 Q422059

Safety profile

Curcumin

Common side effects

  • nausea
  • diarrhea
  • dyspepsia
  • yellow stool (benign)

Contraindications

  • active gallstones (curcumin stimulates gallbladder contraction)
  • severe biliary obstruction
  • scheduled elective surgery (discontinue 1-2 weeks prior)

Interactions

  • warfarin and DOACs: additive antiplatelet and anticoagulant effects; meaningful bleeding risk at 1000+ mg/day(major)
  • aspirin and NSAIDs: additive antiplatelet effect(moderate)
  • tacrolimus and cyclosporine: CYP3A4 and P-gp modulation may alter drug levels(moderate)
  • iron supplements: curcumin chelates iron; can contribute to deficiency in marginal patients(moderate)
  • chemotherapy agents: potential interference with multiple agents; coordinate with oncology team(major)

PT-141

Common side effects

  • nausea (~40%)
  • flushing
  • headache
  • injection-site reactions
  • hyperpigmentation (focal, gums, face, breasts)
  • transient blood pressure increase (~6 mmHg systolic)

Contraindications

  • uncontrolled hypertension
  • established cardiovascular disease
  • pregnancy
  • naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)

Interactions

  • naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
  • antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
  • PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)

Which Should You Take?

Curcumin comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. PT-141 is the right call when one of the conditionals below applies.

  • If your priority is post-training recovery, pick Curcumin.
  • If your priority is healthspan extension, pick Curcumin.
  • If your priority is sexual function, pick PT-141.
  • If your priority is libido, pick PT-141.

Edge case: If you want to avoid research-only / gray-market sourcing, Curcumin is the more accessible choice.

Default choice: Curcumin. Lower friction to source, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Curcumin and PT-141?

Curcumin and PT-141 differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Curcumin or PT-141?

Curcumin half-life is 7 hours; PT-141 half-life is 2.7 hours.

Can you stack Curcumin with PT-141?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper